Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Fasching, P. A.
Bardia, A.
Nusch, A.
Jerusalem, G.
Chan, A.
El Saghir, N.
Alba, E.
Im, S-A.
Janni, W.
Chandiwana, D.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
